Core Viewpoint - 加科思-B (01167) has seen a significant stock price increase of over 11%, currently trading at 8.69 HKD, with a transaction volume of 73.82 million HKD, following the announcement of a capital increase and equity transfer agreement with Haisheng Capital [1] Group 1: Financial Developments - The company has received an initial payment of 125 million RMB from Haisheng Capital, which enhances its cash reserves and supports the development of its innovative oncology therapy pipeline [1] - The agreement includes a milestone payment of 75 million RMB, with Haisheng Capital acquiring 80% of the equity in Beijing Gakos under the terms of the capital increase and equity transfer agreement [1] Group 2: Strategic Focus - Following the completion of the transaction, the company's stake in Gakos will decrease to 10%, aligning with its strategic focus on key pipeline products targeting different critical cellular pathways in oncology [1]
港股异动 | 加科思-B(01167)再涨超11% 近期收到海松资本1.25亿元首付款 公司此前出售非核心项目